Medlab Clinical Ltd is an Australian, publicly listed biotechnology company that formulates and enhances viable therapeutic solutions. Our team of scientists, researchers and doctors are dedicated to building products that are scientifically optimised for a better life. Proudly validated by patents and R&D milestones, the quality and safety of our products set us apart as a world-class offering. We can deliver more for human health and beyond. Medlab is finding new ways to address the biggest challenges of our time, including the growing burden of chronic conditions, suboptimal pain management as well as enhancing drug delivery options with nanotechnology. We are specialising in solutions in the field of oncology with our leading novel drug candidate is an opioid alternative for cancer-induced pain management. Life expectancy for cancer patients has improved yet there has been little advancement in the management of cancer pain. Opioids and opioid derivatives remain the main method of treatment of cancer-related pain, despite there being little evidence for long-term efficacy and known risk of side effects.